Nivolumab is an immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody, which disrupts the interaction of the PD-1 receptor with its ligands, thereby stimulating a memory response to tumor antigen-specific T cell proliferation [22]. The gene discussed is PDCD1; the disease is neoplasm.